TENS and Compression for Established Oxaliplatin-Induced Peripheral Neuropathy
NCT: NCT07409987 · COMPLETED
Brief Summary
Chemotherapy-induced peripheral neuropathy is a clinically important adverse effect of oxaliplatin-based chemotherapy that may cause sensory symptoms, neuropathic pain, functional limitations, and reduced quality of life. This randomized, open-label, four-arm parallel study evaluated the comparative effects of transcutaneous electrical nerve stimulation (TENS), compression, sequential compression followed by TENS, and usual care in 140 adults with metastatic gastrointestinal cancer who developed Grade 2 or higher chemotherapy-induced peripheral neuropathy after the first cycle of oxaliplatin-based chemotherapy. Participants were allocated in a 1:1:1:1 ratio. The primary outcome was the change in the EORTC QLQ-CIPN20 total score from baseline before Cycle 2 to Cycle 6. Quality of life, neuropathy grade, and neuropathic pain were evaluated as secondary outcomes. A prespecified exploratory assessment was also conducted 6 months after Cycle 6.
Frequently Asked Questions
What is TENS and Compression for Established Oxaliplatin-Induced Peripheral Neuropathy?
TENS and Compression for Established Oxaliplatin-Induced Peripheral Neuropathy is a clinical trial registered under NCT07409987. Current status: COMPLETED.
What is the status of NCT07409987?
The current status of NCT07409987 (TENS and Compression for Established Oxaliplatin-Induced Peripheral Neuropathy) is: COMPLETED.
When did TENS and Compression for Established Oxaliplatin-Induced Peripheral Neuropathy start?
TENS and Compression for Established Oxaliplatin-Induced Peripheral Neuropathy started on 2024-08-02.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.